Literature DB >> 18023902

Optimum dose range for the amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment.

Fred Ronald Burlage1, Judith M Roesink, Hette Faber, Arjan Vissink, Johannes A Langendijk, Harm H Kampinga, Rob P Coppes.   

Abstract

BACKGROUND: To determine dose and time dependency of pilocarpine pre-treatment protection from late damage after unilateral irradiation of the rat parotid gland. METHODS AND MATERIALS: The right parotid gland of saline (1mg/ml) or pilocarpine (4 mg/kg) pre-treated rats was irradiated with 10, 15 and 20 Gy. Saliva was collected from the irradiated and shielded parotid before, 30, 60, 120 and 240 days after irradiation. The number of acinar cells/gland was determined 30, 120 and 240 days after irradiation by histological examination.
RESULTS: Pilocarpine pre-treated rats, protection of parotid gland function was seen in the early-intermediate phase (0-120 days) after 15 Gy and in the late phase (>120 days) after 10 and 15 Gy. Although no protection was observed after 20 Gy, a stimulatory effect of pilocarpine on the non-irradiated gland resulted in a significant increase in total saliva secretion. The increase in function after pilocarpine treatment was paralleled by a significant increase in the number of acinar cells in both the irradiated and shielded glands.
CONCLUSIONS: Pre-irradiation treatment with pilocarpine induces compensatory response, at lower doses, in the irradiated and at higher doses in the non-irradiated gland reducing late damage, due to stimulation of unirradiated or surviving cells to divide.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18023902     DOI: 10.1016/j.radonc.2007.10.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.

Authors:  Arjan Vissink; James B Mitchell; Bruce J Baum; Kirsten H Limesand; Siri Beier Jensen; Philip C Fox; Linda S Elting; Johannes A Langendijk; Robert P Coppes; Mary E Reyland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-15       Impact factor: 7.038

Review 2.  Prevention and treatment of radiotherapy-induced side effects.

Authors:  Lara Barazzuol; Rob P Coppes; Peter van Luijk
Journal:  Mol Oncol       Date:  2020-06-24       Impact factor: 6.603

3.  Radioprotective effect of lidocaine on neurotransmitter agonist-induced secretion in irradiated salivary glands.

Authors:  Yu-xiong Su; Geza A Benedek; Peter Sieg; Gui-qing Liao; Andreas Dendorfer; Birgit Meller; Dirk Rades; Matthias Klinger; Samer G Hakim
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

Review 4.  South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy.

Authors:  N Rajendra Prasad; Ganesan Muthusamy; Mohana Shanmugam; Suresh V Ambudkar
Journal:  Cancers (Basel)       Date:  2016-03-05       Impact factor: 6.639

Review 5.  The role of stem cells in the prevention and treatment of radiation-induced xerostomia in patients with head and neck cancer.

Authors:  Daan Nevens; Sandra Nuyts
Journal:  Cancer Med       Date:  2016-02-16       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.